Opinion|Videos|January 16, 2024
Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Advertisement
Episodes in this series
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
2
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
3
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5